911 related articles for article (PubMed ID: 35750137)
1. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
Peiseler M; Schwabe R; Hampe J; Kubes P; Heikenwälder M; Tacke F
J Hepatol; 2022 Oct; 77(4):1136-1160. PubMed ID: 35750137
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease.
Puengel T; Liu H; Guillot A; Heymann F; Tacke F; Peiseler M
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269812
[TBL] [Abstract][Full Text] [Related]
3. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
Tacke F; Puengel T; Loomba R; Friedman SL
J Hepatol; 2023 Aug; 79(2):552-566. PubMed ID: 37061196
[TBL] [Abstract][Full Text] [Related]
4. Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
Kotsiliti E; Leone V; Schuehle S; Govaere O; Li H; Wolf MJ; Horvatic H; Bierwirth S; Hundertmark J; Inverso D; Zizmare L; Sarusi-Portuguez A; Gupta R; O'Connor T; Giannou AD; Shiri AM; Schlesinger Y; Beccaria MG; Rennert C; Pfister D; Öllinger R; Gadjalova I; Ramadori P; Rahbari M; Rahbari N; Healy ME; Fernández-Vaquero M; Yahoo N; Janzen J; Singh I; Fan C; Liu X; Rau M; Feuchtenberger M; Schwaneck E; Wallace SJ; Cockell S; Wilson-Kanamori J; Ramachandran P; Kho C; Kendall TJ; Leblond AL; Keppler SJ; Bielecki P; Steiger K; Hofmann M; Rippe K; Zitzelsberger H; Weber A; Malek N; Luedde T; Vucur M; Augustin HG; Flavell R; Parnas O; Rad R; Pabst O; Henderson NC; Huber S; Macpherson A; Knolle P; Claassen M; Geier A; Trautwein C; Unger K; Elinav E; Waisman A; Abdullah Z; Haller D; Tacke F; Anstee QM; Heikenwalder M
J Hepatol; 2023 Aug; 79(2):296-313. PubMed ID: 37224925
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.
Fougerat A; Montagner A; Loiseau N; Guillou H; Wahli W
Cells; 2020 Jul; 9(7):. PubMed ID: 32650421
[TBL] [Abstract][Full Text] [Related]
6. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
Li X; Wang Z; Klaunig JE
Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
[TBL] [Abstract][Full Text] [Related]
7. Nuclear receptors and nonalcoholic fatty liver disease.
Cave MC; Clair HB; Hardesty JE; Falkner KC; Feng W; Clark BJ; Sidey J; Shi H; Aqel BA; McClain CJ; Prough RA
Biochim Biophys Acta; 2016 Sep; 1859(9):1083-1099. PubMed ID: 26962021
[TBL] [Abstract][Full Text] [Related]
8. Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation.
Yahoo N; Dudek M; Knolle P; Heikenwälder M
J Hepatol; 2023 Aug; 79(2):538-551. PubMed ID: 36893854
[TBL] [Abstract][Full Text] [Related]
9. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
10. Treating inflammation to combat non-alcoholic fatty liver disease.
Wiering L; Tacke F
J Endocrinol; 2023 Jan; 256(1):. PubMed ID: 36259984
[TBL] [Abstract][Full Text] [Related]
11. Reprogramming of Hepatic Metabolism and Microenvironment in Nonalcoholic Steatohepatitis.
Rui L; Lin JD
Annu Rev Nutr; 2022 Aug; 42():91-113. PubMed ID: 35584814
[TBL] [Abstract][Full Text] [Related]
12. Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD).
Qiu YY; Zhang J; Zeng FY; Zhu YZ
Pharmacol Res; 2023 Jun; 192():106786. PubMed ID: 37146924
[TBL] [Abstract][Full Text] [Related]
13. The Multifaceted Roles of Macrophages in NAFLD Pathogenesis.
Vonderlin J; Chavakis T; Sieweke M; Tacke F
Cell Mol Gastroenterol Hepatol; 2023; 15(6):1311-1324. PubMed ID: 36907380
[TBL] [Abstract][Full Text] [Related]
14. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
[TBL] [Abstract][Full Text] [Related]
15. Crucial role of T cells in NAFLD-related disease: A review and prospect.
Mao T; Yang R; Luo Y; He K
Front Endocrinol (Lausanne); 2022; 13():1051076. PubMed ID: 36457551
[TBL] [Abstract][Full Text] [Related]
16. Therapies in non-alcoholic steatohepatitis (NASH).
Oseini AM; Sanyal AJ
Liver Int; 2017 Jan; 37 Suppl 1(Suppl 1):97-103. PubMed ID: 28052626
[TBL] [Abstract][Full Text] [Related]
17. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
18. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
Musso G; Saba F; Cassader M; Gambino R
Prog Lipid Res; 2023 Jul; 91():101238. PubMed ID: 37244504
[TBL] [Abstract][Full Text] [Related]
19. Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies.
Wang GY; Zhang XY; Wang CJ; Guan YF
World J Gastroenterol; 2023 Jan; 29(1):75-95. PubMed ID: 36683713
[TBL] [Abstract][Full Text] [Related]
20. Hepatic inflammatory responses in liver fibrosis.
Hammerich L; Tacke F
Nat Rev Gastroenterol Hepatol; 2023 Oct; 20(10):633-646. PubMed ID: 37400694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]